Encouraging phase 1 trial results for GLPG5201, a CAR T-cell therapy

[bennevisplace]

Introducing the Phase I EUPLAGIA-1 study (EudraCT 2021-003815-25), which investigated GLPG5201, a CD19 CAR T-cell therapy, in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT). Patients enrolled in the study received a freshly manufactured product, with a median vein-to-vein time of 7 days. This CAR-T therapy showed encouraging efficacy with a tolerable safety profile.

vjhemonc.com/video/cc8pjzj8... - includes a 4 minute video. The speaker, Valentin Ortiz-Maldonado, MD, predicted a phase 2 study would "maybe" start next year.

For further details of the study, see ash.confex.com/ash/2023/web...

[AussieNeil Partner Administrator]

Thanks!

Nice to see another CAR-T entry to add to my post on new treatment options healthunlocked.com/cllsuppo...

[bennevisplace in reply to AussieNeil]

Thanks, that post of yours is a virtual encyclopaedia already! You might consider yet another reference for the section on combination BTKi/ Venetoclax treatments, which also covers BTK and BCL2 resistance mechanisms healthunlocked.com/cllsuppo...

In the CAPTIVATE trial the researchers looked for known resistance mutations in BTK PLCG2 and BCL2 in patients with PD at a median follow-up of 38.9 months. They found none, leading to the possibility that the synergy of the Ibr-Ven combination extends to suppression of these resistance mutations. aacrjournals.org/clincancer...

[Spark_Plug]

I'd like to know what the range of process time was, 7 days median is relatively quick.🙂

[bennevisplace in reply to Spark_Plug]

GLPG5201 was manufactured for all pts and administered as a fresh infusion. Median vein-to-vein time was 7 days (range 7–14). ash.confex.com/ash/2023/web... which gives quite a lot of detail about the Phase 1 trial.